Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- ESCIScopus
- 저널 순위
- JCR Q1Scopus Q2
- 저널
- KIDNEY MEDICINE6(8) · 2024
- 피인용
- Scopus 27
- FWCI (Scopus)
- 3.55
- JCR IF
- JCR 2023 3.2
- ISSN
- 2590-0595
저자
- Dixon, Bradley P.제1저자교신저자Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO
- Kavanagh, DavidNational Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
- Aris, Alvaro Domingo MadridChildren's Nephrology and Renal Transplantation Service, Children's Maternity Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain
- Adams, BrigitteDepartment of Pediatric Nephrology, Children's Hospital Queen Fabiola, Universite libre de Bruxelles, Brussels, Belgium
- Kang, Hee GyungDivision of Pediatric Nephrology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea
- Wang, EdwardAlexion, AstraZeneca Rare Disease, Boston, MA
- Garlo, KatherineAlexion, AstraZeneca Rare Disease, Boston, MA
- Ogawa, MasayoAlexion, AstraZeneca Rare Disease, Boston, MA
- Amancha, PraveenAlexion, AstraZeneca Rare Disease, Boston, MA
- Chakravarty, SourishAlexion, AstraZeneca Rare Disease, Boston, MA
- Heyne, NilsSection of Nephrology and Hypertension, Department of Internal Medicine IV, University Hospital Tubingen, Tubingen, Germany
- 김성헌Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Republic of Korea
- Cataland, SperoDivision of Hematology, The Ohio State University Medical Center, Columbus, OH
- Yoon, Sung-SooDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- Miyakawa, YoshitakaDepartment of Hematology, Saitama Medical University, Saitama, Japan
- Luque, YosuRenal Intensive Care Unit, Nephrology Department, Tenon Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne Universite, Paris, France
- Muff-Luett, MelissaDivision of Pediatric Nephrology, University of Nebraska Medical Center, Omaha, NE
- Tanaka, KazukiDepartment of Nephrology, Aichi Children's Health and Medical Center, Aichi, Japan
- Greenbaum, Larry A.Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
초록
Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes of ravulizumab in adults and pediatric patients with aHUS. Study Design: This analysis reports 2-year data from 2 phase 3, single-arm studies. Setting & Participants: One study included C5i-naïve adults (NCT02949128), and the other included 2 cohorts of pediatric patients (C5i-naïve and those who switched to ravulizumab from eculizumab [pediatric switch patients]; NCT03131219). Exposure: Patients received intravenous ravulizumab every 4-8 weeks, with the dose depending on body weight. Outcomes: The primary endpoint in the studies of C5i-naïve patients was complete TMA response, which consisted of platelet count normalization, lactate dehydrogenase normalization, and ≥25% improvement in serum creatinine concentrations from baseline, at 2 consecutive assessments ≥4 weeks apart. Analytical Approach: All analyses used descriptive statistics. No formal statistical comparisons were performed. Results: In total, 86 and 92 patients were included in efficacy and safety analyses, respectively. Complete TMA response rates over 2 years were 61% and 90% in C5i-naïve adults and pediatric patients, respectively. The median increase in estimated glomerular filtration rate from baseline was maintained over 2 years in C5i-naïve adults (35 mL/min/1.73 m2) and pediatric patients (82.5 mL/min/1.73 m2). Most adverse events and serious adverse events occurred during the first 26 weeks. No meningococcal infections were reported. Improvement in the Functional Assessment of Chronic Illness Therapy – Fatigue score achieved by 26 weeks was maintained over 2 years. Limitations: Limitations were the small sample of pediatric switch patients and limited availability of genetic data. Conclusions: Long-term treatment with ravulizumab is well tolerated and associated with improved hematologic and renal parameters and quality of life in adults and pediatric patients with aHUS. Plain-Language Summary: This research tested a drug called ravulizumab for the treatment of atypical hemolytic uremic syndrome (aHUS). aHUS is a rare disease that causes clots in tiny blood vessels. This can damage the kidneys and other organs. We analyzed data from 2 clinical trials in which children and adults with aHUS received ravulizumab through a tube placed in a vein (intravenous line). They received ravulizumab every 4-8 weeks depending on their weight. We found that treating patients for 2 years with ravulizumab was associated with improved blood health, kidney function, and quality of life and was well tolerated. These results support ravulizumab as a long-term treatment for people with aHUS.
키워드
Adultatypical hemolytic uremic syndromecomplement C5 inhibitorefficacyhematologynephrologypediatricravulizumabsafetythrombotic microangiopathy
식별자
- Scopus EID
- 2-s2.0-85198062971



로그인
연구물 목록으로